<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The prognostic significance of the peripheral blood absolute lymphocyte count (ALC) has been carefully examined in lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, but the importance of the baseline ALC in <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> is less clear </plain></SENT>
<SENT sid="1" pm="."><plain>In a recent analysis of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) associated with deletion of chromosome 5q, we observed that an ALC &lt; 1.2x 10(9) cells/L at diagnosis is independently associated with poorer survival </plain></SENT>
<SENT sid="2" pm="."><plain>Clinicopathological data from 503 patients with non-del(5q) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> evaluated at Mayo Clinic between 1996 and 2007 were reviewed to determine the prognostic impact of ALC at diagnosis in non-del(5q) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and an ALC at diagnosis &gt; or =1.2x 10(9) (N = 248) experienced a superior overall survival (OS) compared with patients with an ALC &lt; 1.2x 10(9)/L (N = 255, median OS of 26.6 months versus 18.5 months, P &lt; 0.001, respectively) </plain></SENT>
<SENT sid="4" pm="."><plain>ALC at diagnosis was an independent predictor for OS when compared with the International Prognostic Scoring System and the WHO-based Prognostic Scoring System </plain></SENT>
<SENT sid="5" pm="."><plain>This study suggests that ALC at diagnosis is a prognostic factor for OS in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and argues in favor of further studies to assess the role of host immunity in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> clinical outcomes </plain></SENT>
</text></document>